Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eye care device company Luneau targets Euronext IPO

This article was originally published in Clinica

Executive Summary

French ophthalmic equipment specialist Luneau Technology is aiming to raise funds by floating on the Euronext's Alternext market for small- to medium-sized firms. The Chartres-based firm is offering around 825,000 new shares at a price range of E4.64-5.06 from January 15-28 and expects to begin trading on the Paris branch of the Alternext on February 4. Depending on the demand for its shares, Luneau could exercise an extension option and offer an extra 124,000 shares, as well as a Greenshoe option and offer an additional 82,000 to existing shareholders depending on its performance during its first month on the exchange. The Greenshoe option aims to provide stability to an initial public offering post-pricing. Luneau manufactures various devices and accessories for diagnostic and surgical treatment, including keratometers, tonometers and retinographs. It also makes and sells gynaecology materials.

You may also be interested in...



Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

Hair Supplement Linked To Cases Of Severe Hepatitis In France

France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.

AZ Will Sideline ‘Lucky Mistake’ Data To Secure COVID-19 Vaccine Approval

A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel